The study tests two treatment regimens: volrustomig plus chemotherapy (carboplatin with either pemetrexed or paclitaxel) and pembrolizumab plus the same chemotherapy options. Volrustomig is an ...

In March 2024, Lantern dosed two subjects in a Phase Ia/Ib trial of LP-284 for relapsed or refractory non-Hodgkin’s lymphoma ...

Lantern Pharma (NASDAQ: LTRN), an AI-driven developer of targeted cancer therapies using its proprietary RADR (R) platform, has completed targeted enrollment for its Phase 2 HARMONIC (TM) clinical ...

Detailed price information for Lantern Pharma Inc (LTRN-Q) from The Globe and Mail including charting and trades.

Adding ICIs to chemotherapy ± antiangiogenic therapy improves survival outcomes in advanced NSCLC that is resistant to EGFR-TKIs.

New long-term data from the Phase III FLAURA2 trial confirm that Tagrisso combined with chemotherapy delivers a significant overall survival benefit over monotherapy in patients with advanced ...

This strategy is moving forward in development. They are looking only for the PD-L1–high patients with this combination, and then in the PD-L1 negative or moderate [population], it will be a ...

AstraZeneca's Tagrisso combined with pemetrexed and platinum-based chemotherapy has shown improvement in overall survival (OS).

Pemetrexed ditromethamine injection: Pfizer has discontinued the manufacture of pemetrexed ditromethamine injection in 100- and 500-milligram single-dose vials, an oncology drug used to treat ...

TAGRISSO is indicated in combination with pemetrexed and platinum-based chemotherapy, for the first-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have ...

The FLAURA2 trial, a randomized, open-label, multicenter, global, phase 3 study, compared osimertinib monotherapy with osimertinib plus chemotherapy (pemetrexed and cisplatin or carboplatin) in 557 ...